Amendments to the Claims:

1-46. (Canceled without Prejudice)

47. (Currently Amended) A method for inducing death in cancer cells that express an apoptosis-mediating receptor, the method comprising:

introducing an ~~expression~~ adenoviral vector encoding an apoptosis-signaling ligand into cancer cells that express an apoptosis-mediating receptor, ~~—a group of cells comprising cells that express an apoptosis-mediating receptor, the expression vector comprising a polynucleotide sequence encoding an apoptosis-signaling ligand whose expression is regulated by a conditional promoter in the vector, the cells into which the expression vector is introduced expressing the apoptosis-signaling ligand when conditions are suitable to activate the conditional promoter, the expressed apoptosis-signaling ligand inducing cell death in those cells which express the apoptosis-mediating receptor~~

wherein expression of the apoptosis-signaling ligand in the cancer cells induces apoptosis through ~~interaction between~~ specific binding of the apoptosis-signaling ligand ~~and~~ to the apoptosis-mediating receptor.

48-57. (Canceled without Prejudice)

58. (Currently Amended) The method of claim 47, wherein the ~~group of~~ cancer cells are contained in a solid tumor.

59. (Previously Presented) The method of claim 58, wherein the solid tumor is selected from the group consisting of breast, prostate, brain, bladder, pancreas, rectum, parathyroid, thyroid, adrenal, head and neck, colon, stomach, bronchi and kidney tumors.

60. (Currently Amended) The method of claim 47, wherein introducing an ~~expression~~ adenoviral vector into the ~~group of~~ cancer cells is performed parenterally, intraperitoneally, intravenously, intraartierally, transdermally, sublingually, intramuscularly, rectally,

transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery by catheter or stent, subcutaneously, intraadiposally, intraarticularly, intrathecally, or in a slow release dosage form.

61. (Currently Amended) The method of claim 47, wherein introducing the ~~expression~~ adenoviral vector is performed by direct injection of the ~~expression~~ adenoviral vector among ~~the group of~~ cancer cells.

62-65. (Canceled)

66. (Currently Amended) The method of claim 47, wherein ~~the conditional promoter is~~ the expression of the apoptosis-signaling ligand is controlled by a tissue-specific promoter in the adenoviral vector.

67. (Previously Presented) The method of claim 66, wherein the tissue-specific promoter is selected from the group consisting of a prostate-specific promoter, a breast-specific promoter, a pancreas-specific promoter, a colon-specific promoter, a brain-specific promoter, a kidney-specific promoter, a bladder-specific promoter, a lung-specific promoter, a liver-specific promoter, a thyroid-specific promoter, a stomach-specific promoter, an ovary-specific promoter, and a cervix-specific promoter.

68. (Currently Amended) The method of claim 47, wherein the ~~group of~~ cancer cells are prostate cancer cells and ~~the conditional promoter of the expression vector is~~ the expression of the apoptosis signaling ligand is controlled by a prostate-specific promoter in the adenoviral vector.

69. (Previously Presented) The method of claim 68, wherein the prostate-specific promoter is selected from the group consisting of PSA, ΔPSA, ARR2PB, and PB promoters.

70. (Currently Amended) The method of claim 47, wherein ~~the conditional promoter is~~ the expression of the apoptosis-signaling ligand is controlled by an inducible promoter in the adenoviral vector.

71. (Previously Presented) The method of claim 70, wherein the inducible promoter is a promoter inducible by tetracycline or doxycycline.

72. (Previously Presented) The method of claim 70, wherein the inducible promoter is a promoter inducible by steroid.

73. (Previously Presented) The method of claim 72, wherein the steroid is selected from the group consisting of glucocorticoid, estrogen, androgen, and progestrone.

74-112. (Canceled without Prejudice).

113. (New) The method of claim 47, wherein the apoptosis-signaling ligand is Fas ligand.

114. (New) The method of claim 47, wherein the apoptosis-mediating receptor is Fas.

115. (New) The method of claim 47, wherein the adenoviral vector further comprises a polynucleotide sequence encoding a reporter protein.

116. (New) The method of claim 115, wherein the reporter protein and the apoptosis-signaling ligand are encoded as a fusion protein.

117. (New) The method of claim 116, wherein the reporter protein is a green fluorescent protein.

118. (New) The method of claim 47, wherein the adenoviral vector is Ad_{TET}.

119. (New) The method of claim 47, wherein the adenoviral vector is Ad/FasL-GFP_{TET}.